CoChat

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

Open access
Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C. · 2009 · British Journal of Haematology
Cited by 113

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre‐clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre‐clinical activity against CLL cells with a LC 50 (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty‐one patients received a median of two cycles of MGCD0103 (range, 0–12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3–4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2009.07881.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 113

Metadata

Authors
Blum, K. A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., Kassis, J., Davis, M., Bonfils, C., Dubay, M., Dumouchel, J., Drouin, M., Lucas, D. M., Martell, R. E., & Byrd, J. C.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2009-10-27
Volume
147
Issue
4
Pages
507-514
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2160457008
Cited by
113
References
1
FWCI
4.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. https://app.cochat.ai/papers/10.1111/j.1365-2141.2009.07881.x
The paper
Blum, K. A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., Kassis, J., Davis, M., Bonfils, C., Dubay, M., Dumouchel, J., Drouin, M., Lucas, D. M., Martell, R. E., & Byrd, J. C. (2009). Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2009.07881.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.